Transfusion requirement
| . | Control . | Intervention . | P . |
|---|---|---|---|
| ITT analysis | |||
| Transfusion-treatment periods, n | 279 | 277 | |
| Red cell transfusions, median (IQR), n | 4 (2-7) | 4 (2-6) | .135 |
| Plasma transfusions, median (IQR), n | 0 (0-0) | 0 (0-0) | .842 |
| PLT transfusion interval, mean (95% CI), h* | 83 (77-91) | 71 (67-77) | .002 |
| PLT transfusions per transfusion-treatment period, median (IQR), n | 4 (2-7) | 5 (2.5-7.5) | .328 |
| Per-protocol analysis | |||
| Transfusion-treatment periods, n | 220 | 205 | |
| Red cell transfusions, median (IQR), n | 3 (2-6) | 3 (2-5) | .34 |
| Plasma transfusions, median (IQR), n | 0 (0-0) | 0 (0-0) | .59 |
| PLT transfusion interval, mean (95% CI), h* | 91 (83-100) | 71 (67-77) | <.001 |
| PLT transfusions per transfusion-treatment period, median (IQR), n | 3 (2-6.75) | 5 (3-7.5) | .085 |
| . | Control . | Intervention . | P . |
|---|---|---|---|
| ITT analysis | |||
| Transfusion-treatment periods, n | 279 | 277 | |
| Red cell transfusions, median (IQR), n | 4 (2-7) | 4 (2-6) | .135 |
| Plasma transfusions, median (IQR), n | 0 (0-0) | 0 (0-0) | .842 |
| PLT transfusion interval, mean (95% CI), h* | 83 (77-91) | 71 (67-77) | .002 |
| PLT transfusions per transfusion-treatment period, median (IQR), n | 4 (2-7) | 5 (2.5-7.5) | .328 |
| Per-protocol analysis | |||
| Transfusion-treatment periods, n | 220 | 205 | |
| Red cell transfusions, median (IQR), n | 3 (2-6) | 3 (2-5) | .34 |
| Plasma transfusions, median (IQR), n | 0 (0-0) | 0 (0-0) | .59 |
| PLT transfusion interval, mean (95% CI), h* | 91 (83-100) | 71 (67-77) | <.001 |
| PLT transfusions per transfusion-treatment period, median (IQR), n | 3 (2-6.75) | 5 (3-7.5) | .085 |
IQR, interquartile range; PLT, platelet.
Using all treatment periods via mixed Poisson model.